Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe

Table 3 Estimated annual number of new precancerous lesions in women and men in Europe

Precancerous lesion	New precancerous lesions (range)	New precancerous lesions attributable to all HPV types (range)	New precancerous lesions attributable to 9-valent HPV vaccine types (6/11/16/18/31/33/45/52/58) (range)
CIN 2+	263,227 – 503,010	263,227 – 503,010	216,636 – 413,977
VIN 2/3	13,997 – 27,773	12,164 – 24,135	11,482 – 22,783
VaIN 2/3	2,596 – 4,751	2,487 – 4,551	1,930 – 3,532
AIN 2/3 (F)	1,549	1,477	1,203
AIN 2/3 (M)	1,097	1,045	852
Total (both sexes)	282,466 - 538,180	280,399 - 534,218	232,103 - 442,347

HPV human papillomavirus, CIN2+ cervical intraepithelial neoplasia grade 2 or worse, VIN2/3 vulvar intraepithelial neoplasia grades 2 and 3, VaIN2/3 vaginal intraepithelial neoplasia grades 2 and 3, AIN2/3 anal intraepithelial neoplasia grades 2 and 3, CIN 2+ includes CIN2/3 and AIS, N number, F female, M male

ISSN: 1750-9378